Suki AI vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Redwood City ambient voice AI for physicians converting patient conversations into EHR-coded SOAP notes and diagnoses; integrates with major EHR systems to reduce documentation time.
About
Suki AI is a Redwood City-based clinical AI company that provides physicians with an ambient voice assistant that listens to patient-physician conversations during appointments and automatically generates structured clinical notes in the EHR, dramatically reducing the documentation burden that contributes to physician burnout. Suki's AI processes natural conversation audio to extract clinically relevant information, populate SOAP notes, and code diagnoses and procedures — turning a 15-minute documentation task into a 2-minute review and sign-off. The platform integrates with major EHR systems including Epic, Cerner, and Athena and is designed to fit naturally into clinical workflows without requiring physicians to change how they see patients. Suki serves health systems, physician groups, and telehealth companies looking to improve clinician efficiency and satisfaction. Founded in 2017 by former Google and Flipkart executives, Suki raised over $165M from investors including Venrock, First Round Capital, and Flare Capital Partners. It competes with Nuance DAX, Abridge, and DeepScribe in the ambient AI documentation market.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.